School of Chinese Medicine
Paclitaxel is an anti-tumor agent with remarkable anti-tumor activity and wide clinical uses. However, it is also faced with various challenges especially for its poor water solubility and low selectivity for the target. To overcome these disadvantages of paclitaxel, approaches using small molecule modifications and macromolecule modifications have been developed by many research groups from all over the world. In this review, we discuss the different strategies especially prodrug strategies that are currently used to make paclitaxel more effective.
paclitaxel, poor water solubility, low selectivity, prodrug
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
This study was supported by the Hong Kong General Research Fund (HKBU12102914 to Ge Zhang) and the Faculty Research Grant of Hong Kong Baptist University (FRG2/12-13/027 to Ge Zhang).
Link to Publisher's Edition
Meng, Z., Lv, Q., Lu, J., Yao, H., Lv, X., Jiang, F., Lu, A., & Zhang, G. (2016). Prodrug strategies for paclitaxel. https://doi.org/10.3390/ijms17050796